Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.

A 2-year-old girl’s death in Akron has led to Hyundai Palisade recall and sales halt over concerns about power-folding seat ...

Micron sales, profits soar to new heights: Micron Technology, which broke ground in January on a massive chipmaking complex in Central New York, blew past its own and analysts’ expectations today by ...

Luxury condo development in San Francisco and the Bay Area is showing strong signs of revival, though it will be a while before buyers can get their hands on it. “Low inventory levels in the ...

Salesforce architect Ranjith Kumar Kollu designs scalable, automated CRM systems that replace manual workflows with high-performance, integrated enterprise solutions.